BioSpace News Archive

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to create product candidates that address unmet medical needs, today announced that the company will participate at the Oppenheimer 31st Annual Healthcare Conference. Company executives will provide a business overview and an update on the Company’s pipeline programs.

New Findings from Ongoing Collaborations with University of Alabama at Birmingham and Saint Louis University Studies Show Complete Protection Against Lethal Challenge and Dramatic Reduction in Viral Replication Systemic and Mucosal Antibody Responses Durable for at Least 6 Months

Company had $120.9 million of cash and cash equivalents as of March 12, 2021 Substantial increase in liquidity driven by equity investment from Suvretta Capital and sale of Arvelle shares Company estimates it is fully funded through major upcoming milestones for GM1 gene therapy program

BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that BXCL501, the Company’s investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine (“Dex”), has been granted Breakthrough Therapy designation from the FDA

Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that its Bristol site in the United Kingdom received ISO 9001:2015 Quality Management Systems certification.

Aulos Bioscience, a biotechnology company that is developing highly differentiated interleukin-2 (IL-2)-binding monoclonal antibodies as therapeutics against solid tumors, announced today that Aron Knickerbocker has joined the company as its chief executive officer and a member of its board of directors, effective immediately

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, announces extensive progress in five studies focused on the performance of DehydraTECHTM CBD as a treatment for hypertension.

Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced that an independent Data Safety Monitoring Board (DSMB) has completed its interim review of the company’s Phase 2b GALACTIC-1 study of GB0139 for the treatment of Idiopathic Pulmonary Fibrosis (IPF).

Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 23, 2021 which includes a 35-minute webcast beginning at 1:15 p.m. ET .

Completion of balstilimab BLA filing on target for 1H 2021 New clinical data for AGEN1181 to be presented at AACR TIGIT bispecific AGEN1777 IND to be filed in 2Q 2021 iNKT cell therapy cancer trials to commence in 1H 2021